{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clinical+High-Risk&page=13", "query": { "condition": "Clinical High-Risk", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 455, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clinical+High-Risk&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clinical+High-Risk&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T04:11:21.104Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06389786", "title": "Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Localized Prostate Carcinoma", "Oligometastatic Prostate Carcinoma", "Stage I Prostate Cancer AJCC v8", "Stage II Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Bilateral Pelvic Lymph Node Dissection", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Flotufolastat F-18 Gallium", "type": "OTHER" }, { "name": "Laparoscopic Radical Prostatectomy with Robotics", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "MALE", "summary": "30 Years to 85 Years · Male only" }, "enrollment_count": 50, "start_date": "2024-06-11", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06389786" }, { "nct_id": "NCT06440850", "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Gland Follicular Carcinoma", "Thyroid Gland Oncocytic Carcinoma", "Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "I-131 Uptake Test", "type": "PROCEDURE" }, { "name": "Iodine I-131", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Thyrotropin Alfa", "type": "BIOLOGICAL" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2024-07-15", "completion_date": "2026-11-22", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06440850" }, { "nct_id": "NCT02014103", "title": "Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Complication of Transplant" ], "interventions": [ { "name": "Prograf", "type": "DRUG" }, { "name": "Tacrolimus, Sandoz", "type": "DRUG" }, { "name": "Tacrolimus, Reddy Laboratory", "type": "DRUG" }, { "name": "Tacrolimus, Mylan", "type": "DRUG" }, { "name": "Tacrolimus, Accord", "type": "DRUG" }, { "name": "Tacrolimus, Pancea Biotech Limited", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2015-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02014103" }, { "nct_id": "NCT01771484", "title": "High Sodium Diet and External Abdominal Compression in POTS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Postural Orthostatic Tachycardia Syndrome" ], "interventions": [ { "name": "External automated abdominal binder", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 13, "start_date": "2012-12", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01771484" }, { "nct_id": "NCT03747484", "title": "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Other Skin" ], "interventions": [ { "name": "Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Interferon Gamma-1b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2019-07-03", "completion_date": "2024-01-09", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03747484" }, { "nct_id": "NCT05114733", "title": "Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical High Risk for Psychosis" ], "interventions": [ { "name": "InVEST", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "12 Years to 22 Years" }, "enrollment_count": 26, "start_date": "2022-02-22", "completion_date": "2025-09-15", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05114733" }, { "nct_id": "NCT03601078", "title": "An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "bb2121", "type": "BIOLOGICAL" }, { "name": "Lenalomide", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2018-12-13", "completion_date": "2026-01-15", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03601078" }, { "nct_id": "NCT00666913", "title": "Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Hot Flashes" ], "interventions": [ { "name": "informational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 183, "start_date": "2007-10", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2015-09-29", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666913" }, { "nct_id": "NCT04314635", "title": "A Treatment Engagement Protocol for Psychiatrically Hospitalized Adolescents at Clinical High Risk for Psychosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psychosis Nos/Other" ], "interventions": [ { "name": "Brief family engagement intervention for CHR", "type": "BEHAVIORAL" }, { "name": "Treatment as usual (TAU)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Rhode Island Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "13 Years to 18 Years" }, "enrollment_count": 80, "start_date": "2020-06-29", "completion_date": "2023-11-30", "has_results": false, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 1, "location_summary": "East Providence, Rhode Island", "locations": [ { "city": "East Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04314635" }, { "nct_id": "NCT06750289", "title": "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Asthma" ], "interventions": [ { "name": "ICS-LABA", "type": "COMBINATION_PRODUCT" }, { "name": "benralizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo for Benralizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 130, "start_date": "2025-03-28", "completion_date": "2026-09-21", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-23T04:11:21.104Z", "location_count": 20, "location_summary": "Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Inglewood", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06750289" } ] }